VORVor Biopharma Inc.
+5.7% today · −23.3% over a year
No score: too little data.
Stability: among the weakest; priced higher than most peers (P/E 1.9). No dividend.
Vor Biopharma Inc. (VOR) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €1.1B. Over the past 12 months the price changed by −23.3%, with an annualised volatility of 112% and a largest fall of 73%. Hard red flags in our rules-based screen: Financial distress.
Smart Score
How it is scored →Not scored: not enough data for a fair comparison.
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Share issuance (1 y)weighs on the score · better than 1% of peers
- Volatility (1 y)weighs on the score · better than 3% of peers
- Return on assetssupports the score · better than 100% of peers
Red flags and notes
- Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary → Altman Z in the distress zone and negative free cash flow.
- Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
- Caution. Accruals or the Beneish M-score are in the watch zone. More in the glossary → Accruals or the Beneish M-score are in the watch zone.
- Caution. Book equity is below zero. More in the glossary → Book equity is below zero.
- Caution. At least one reverse split in the last three years. More in the glossary → At least one reverse split in the last three years.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/E
- 1.9
- Free-cash-flow yield
- −11.5%
- Market cap (EUR)
- €1.1B
Dividends
- Dividend yield
- 0.00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- +5.7%
- 1 month
- +12.8%
- 1 year
- −23.3%
- Volatility, 1 yr
- 112.4%
- Max drawdown, 1 yr
- −73.1%
- Beta
- 3.48
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| STAASTAAR Surgical Co | 2/10 | 0.0% | −9.4% |
|---|---|---|---|
| OPKOPKO Health Inc. | 1/10 | 0.0% | 12.5% |
| INNVInnovAge Holding Corp. | 7/10 | 0.0% | 79.1% |
| TDOCTeladoc Health Inc | 3/10 | 0.0% | −17.7% |
| MRVIMaravai LifeSciences Holdings | —/10 | 0.0% | 163.2% |
| ENOVEnovis Corporation | 2/10 | 0.0% | −33.3% |
| OMDAOmada Health Inc. | —/10 | 0.0% | −28.4% |
| USPHUS Physical Therapy Inc | 4/10 | 2.1% | −2.7% |
News and filings
- Vor Biopharma Inc.: 10-Q — Quarterly report for the period ending 30 Jun 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 11 Aug 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 1 entry
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | —/10 | — · — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.